4Bio Partners
4Bio Partners, which trades as 4BIO Capital, is a London-headquartered venture capital firm that invests exclusively in the advanced-therapies sector. It backs early-stage life-science companies developing cell and gene therapies, RNA-based therapies, targeted therapies, radiopharmaceuticals and microbiome treatments addressing areas of high unmet medical and social need. The wider 4BIO Capital business has invested since 2014, while the named UK management entity, 4BIO PARTNERS LLP, was incorporated at Companies House under number OC424585 on 23 October 2018. The firm has invested in more than 25 advanced-therapies companies, with notable outcomes including the public listings of UniQure and Autolus and the trade sales of Orchard Therapeutics and Araris Biotech. It is authorised and regulated by the UK Financial Conduct Authority under firm reference number 842764. Its latest flagship fund, 4BIO Ventures III, is a 2022-vintage vehicle that filed a SEC Form D stating a USD 200 million total offering amount.
Key facts
Recent exits
Coverage notes
1 fund tracked, 12 portfolio companies (11 active · 1 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund 4Bio Partners has raised, with its portfolio companies. Hand-checked from public filings.
4BIO Ventures IIILife Sciences VC2022 · 4yr€184M11 active · 1 realized
Unrealized
11 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Actithera | Biotech | Switzerland | 2025 |
| Ascend Advanced Therapies | Biotech | UK | 2023 |
| Code Biotherapeutics | Biotech | US | 2022 |
| Cytospire Therapeutics | Biotech | UK | 2026 |
| Hornet Therapeutics | Biotech | UK | 2024 |
| LUCA Science | Biotech | Japan | 2022 |
| March Biosciences | Biotech | US | 2024 |
| Ray Therapeutics | Biotech | US | 2021 |
| SparingVision | Biotech | France | 2020 |
| Trogenix | Biotech | UK | 2023 |
| ViaNautis Bio | Biotech | UK | 2023 |
Saved GPs appear in your watchlist, one click from your workspace.
About 4Bio Partners
4BIO Partners (4BIO Capital) is one of the few venture capital firms investing exclusively in advanced therapies with approximately $300 million plus of assets under management as of December 2024 across Ventures II and Ventures III (Ventures III is 2023 vintage, with the Development Bank of Japan joining Ventures III in January 2024), headquartered in London. The firm was founded in 2015 as a specialist VC focused on advanced therapies and operates as 4BIO Partners LLP, FCA-regulated.
Investment thesis
4BIO Partners deploys capital through approximately three funds (4BIO Ventures I, II, III), targeting early-stage venture capital exclusively in advanced therapeutics addressing high unmet medical need. Sector focus spans cell and gene therapy, RNA-based therapeutics, targeted therapies, microbiome and broader advanced and emerging biotech modalities. Geographic deployment is global across the US, UK and Europe, London-based. The platform aims to take advanced therapy modalities (cell, gene, RNA) mainstream.
Recent activity
Recent realised exits include an antibody-drug conjugate and biotech acquisition (2024). Recent investments include oncology viral immunotherapy Series A (2025), gene therapy Series A (2024-2025) and radiopharmaceutical and targeted therapy Series A (2024-2025). The platform continues active deployment of Ventures III across the advanced therapeutics mandate. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
United Kingdom·€309.0BUnited Kingdom·€15.4BUnited Kingdom·€12.7BUnited Kingdom·€11.7BUnited Kingdom·€6.4BUnited Kingdom·€4.1BUnited Kingdom·€3.5BUnited Kingdom·€2.3BUnited Kingdom·€2.3BUnited Kingdom·€1.8BUnited Kingdom·€1.8BUnited Kingdom·€1.6B